SUBSCRIBE
SUBSCRIBE

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

  • 2025 BPTW Badge - RBG.png
  • 2024 - Best Places to Work - Badges - Brighspot Rework - Outlined - 20pt.png
211 Mt. Airy Road
Basking Ridge, NJ 07920
Tel: (908) 992-6400
Visit website
  • Featured Employer
NEWS
HER2 low breast cancer patient
Drug Development
New Data Supports Enhertu’s Benefit in HER2 Low Breast Cancer
AstraZeneca and Daiichi Sankyo released positive data from their Phase III trial of Enhertu. An alternative to chemotherapy for some HER2 low breast cancer.
February 21, 2022
 · 
2 min read
 · 
Rosemary Scott
Drug Development
Lilly, Innovent and the Question of Clinical Trial Representation
The unspoken challenge is: how diverse can a trial run in the United States really be right now?
February 15, 2022
 · 
4 min read
 · 
Heather McKenzie
Business
Adcentrx Links with AvantGen To Advance Superior Antibody-Drug Conjugate Therapies
The three-year agreement leverages AvantGen’s yeast display technology for antibody discovery optimization to engineering antibodies into Antibody-Drug Conjugate treatments.
February 15, 2022
 · 
2 min read
 · 
Vanessa Doctor, RN
Bio NC
BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
January 17, 2022
 · 
6 min read
 · 
Heather McKenzie
Business
Daiichi Sankyo Shuttering Plexxikon Site in Favor of ADCs
Daiichi wants to maximize its investment in three antibody-drug conjugates, which the company has positioned as one of the strategic pillars of its 5-year Business Plan.
January 12, 2022
 · 
3 min read
 · 
Mark Terry
Business
Feeling Collaborative, Merck Inks Three More Deals to Strengthen Portfolio
Merck entered into collaborations with three different companies as it continues to assess Keytruda in combination with experimental drugs in different cancer indications.
October 25, 2021
 · 
4 min read
 · 
Alex Keown
BioMidwest
Clinical Catch-Up: September 20-24
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
September 24, 2021
 · 
12 min read
 · 
Mark Terry
Drug Development
Several Companies Tout Lung Cancer Breakthroughs at ESMO 2021
Lung cancer is a particularly difficult cancer to treat, but several companies presented very promising data at this year’s European Society of Medical Oncology (ESMO) Congress 2021.
September 20, 2021
 · 
4 min read
 · 
Mark Terry
Drug Development
Clinical Catch-Up: August 9-13
There was plenty of clinical trial updates last week. Here’s a look.
August 13, 2021
 · 
5 min read
 · 
Mark Terry
Load More
JOBS
View All Jobs at Daiichi Sankyo
IN THE PRESS
Pharm Country
U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen
February 16, 2023
 · 
2 min read
Pharm Country
TURALIO® New Dosing Regimen Now Available in the U.S. for Certain Patients with Tenosynovial Giant Cell Tumor
February 1, 2023
 · 
14 min read
Drug Development
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
January 30, 2023
 · 
9 min read
Business
Ibex Medical Analytics Enters Collaboration with AstraZeneca and Daiichi Sankyo to Develop AI-based HER2 Scoring Product
January 24, 2023
 · 
5 min read
Job Trends
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
December 22, 2022
 · 
9 min read
Business
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
December 21, 2022
 · 
5 min read
Pharm Country
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer
December 8, 2022
 · 
9 min read
Business
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
December 7, 2022
 · 
8 min read
Drug Development
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
December 7, 2022
 · 
31 min read
Drug Development
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
December 7, 2022
 · 
33 min read
Load More